EglumetadAlternative Names: Eglumegad; LY-354740
Latest Information Update: 29 Oct 2009
At a glance
- Originator Eli Lilly
- Class Anxiolytics; Neuroprotectants; Small molecules; Smoking cessation therapies
- Mechanism of Action Glutamate agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Neuroprotection; Panic disorder; Psychotic disorders; Schizophrenia; Seizures; Smoking withdrawal